Overview
This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.
Eligibility
Inclusion Criteria:
- Age ≥18 years at the start of iptacopan therapy.
- The patient is undergoing treatment with iptacopan.
- The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
- Provision of written informed consent.
Exclusion Criteria:
- Any situations where iptacopan is contraindicated in accordance with the Summary of Product Characteristics.